Sinopep-allsino Biopharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is BIVALIRUDIN, with a corresponding US DMF Number 32281.
Remarkably, this DMF maintains an Active status since its submission on June 29, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 15, 2019, and payment made on September 19, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II